Introduction {#Sec1}
============

Intramural urethral bulking therapy for female urinary incontinence has become increasingly popular among physicians and patients due to its minimally invasive nature. Recent advances have shed light on the working mechanism of bulking agents \[[@CR1]\], and a recent clinical study has documented that bulking therapy is more effective than conservative treatment in terms of pelvic floor training \[[@CR2]\].

Many agents of different make and tissue interaction have been used for urethral bulking. However, in terms of efficacy, no clear conclusions can be drawn from trials comparing alternative agents at the moment \[[@CR3]\]. Safety concerns have been raised with regard to specific agents because of migration \[[@CR4]\], hypersensitivity \[[@CR5]\], urethral erosion \[[@CR6]\], pseudocysts/abscess \[[@CR7]\], and granuloma formation \[[@CR8]--[@CR11]\]. Materials such as paraffin, polytetrafluroethylene, autologous fat, and most recently, ethylene vinyl alcohol (Tegress®) and hyaluronic acid/dextranomer copolymer (Zuidex®) have been abandoned because of safety issues.

In 2006, polyacrylamide hydrogel (PAHG) Bulkamid® was introduced in Europe as a promising new urethral bulking agent \[[@CR12]\]. It is a polymer gel consisting of 2.5% cross-linked polyacrylamide and 97.5% water for injection, which is atoxic \[[@CR13], [@CR14]\] and resistant to degradation \[[@CR15], [@CR16]\]. It has a widespread use in ophthalmic surgery, drug treatment, food packaging, and water purification \[[@CR17]\]. PAHG has been used in plastic surgery for esthetic purposes in the former Soviet Union and China for the past 15 to 20 years, and in Europe for the past 7 \[[@CR18]\]. According to these studies, the gel stays within soft tissues for at least 8 1/2 years after the injection, and gives rise to little or no tissue reaction without capsular fibrosis or calcification \[[@CR15]\]. A recent study in rabbits has shown that the bulking effect is preserved for at least for 7 months \[[@CR13]\], and a study in pigs has documented that PAGH is a stable viscoelastic bulking agent which is being integrated within its host tissue by vessel ingrowth \[[@CR16]\].

The aim of the present study was to investigate the clinical efficacy and safety of PAHG (Bulkamid®) in a larger cohort of women with stress or mixed urinary incontinence.

Materials and methods {#Sec2}
=====================

The study was an open, noncomparative, multicenter, and multinational study including 10 centers in five countries; two centers in Denmark, two in Sweden, one in Finland, four in UK, and one in Germany. The study was performed in accordance with International Conference on Harmonisation Good Clinical Practice Guidelines.

Methods, definitions, and units conform to the standards recommended by the International Continence Society, except where specifically noted \[[@CR19]\].

Patient characteristics {#Sec3}
-----------------------

Women aged ≥18 years were eligible to participate if they had symptomatic stress or mixed incontinence for ≥12 months, and ≥ 1 incontinence episode per 24 h, measured by a 3-day micturition diary. Additional requirements were a maximum flow rate of ≥15 ml/s, a post-void residual urine volume (PVR) of ≤100 ml, a bladder capacity ≥300 ml based on the micturition diary (measured over 3 days) normal diuresis (\<40 ml/kg per 24 h), and no pelvic organ prolapse ≥ stage 2.

Women were excluded if they had an acute urinary tract infection (UTI), allergic reaction to local anesthesia and antibiotics used for prophylaxis, had previous surgery for incontinence including bulking, received ongoing medication for incontinence (except anticholinergics at a constant dose for \>4 weeks), were treated with systemic corticosteroids, or suffered from active autoimmune or connective tissue diseases, or were pregnant.

All women had a screening visit including full medical history, a physical and pelvic examination including genital prolapse (pelvic organ prolapse quantification) score, uroflowmetry, PVR measurement, and urine dipstick test (if positive with culture and sensitivity). The screening visit was followed by a baseline visit collecting data from the 24-h pad-weighting test and estimating bladder capacity, number of micturitions, stress and urge incontinence episodes; diuresis were estimated based on a 3-day micturition diary. In addition, the International Consultation on Incontinence Questionnaire (ICIQ) \[[@CR20]\], as well as a patient quality of life (QoL) visual analogue scale (VAS) score \[[@CR21]\] was filled in. Treatment with PAHG was performed at the baseline visit or within 3 days, and no later than 8 weeks from the screening visit. In case of a UTI at the baseline visit, a new baseline visit could be rescheduled one time.

Treatment and follow-up {#Sec4}
-----------------------

The PAHG injection was administered under local anesthesia. The women were in the lithotomy position, and a total of 10 ml of 5% Lidocaine was injected into the wall of the urethra at 3 and 9 o'clock positions. PAHG was injected transurethrally into the submucosa under urethroscopic control using a 23 G × 120-mm needle with 1 cm markings to enable correct placement of the injection (Bulkamid® cystoscope, Fig. [1](#Fig1){ref-type="fig"}). Fig. 1The Urethroscope, connected to the rotatable sheath, with inflow/outflow tubings. The needle (23G x 12 cm) is placed in the working-canal connected to a 1 ml syringe with Bulkamid

Two or three deposits (0.2--0.8 ml each) were placed 0.5--1 cm distal to the bladder neck at 2, 6, and 10 o'clock positions. The needle was re-sited if the injection appeared to be too superficial, too deep, or if there was extravasation of PAHG into the bladder or urethral lumen. After satisfactory urethral occlusion, the bladder was emptied via the endoscope. During injection, the women received a prophylactic antibiotic treatment, e.g., an i.v. dose of cefuroxime (1.5 g). They were discharged after successful voiding (PVR \<100 ml, assessed by ultrasonography).

The women were reevaluated 1, 6, and 12 months later. The efficacy assessment included patient subjective perception ("cured", "improved", "not changed", or "worsened") \[[@CR22]\]), number of incontinence episodes/24 h, 24-h pad-weighting testing, ICIQ, and VAS score on QoL. Furthermore, urine stix were performed, and measurement of PVR was carried out.

Patients considering themselves for "cured" or "improved" were defined as responders. If they had not gained satisfactory benefit from the first injection at the first-month follow-up visit, they were offered a second treatment within 8 weeks period.

Adverse events were classified as serious or non-serious, and judged to be either related (ADE) or unrelated to the study treatment (AE).

### Data analyses and statistics {#Sec5}

The sample size was estimated based on a binomial distribution. Assuming a success rate of PAHG treatment of at least 50% with a maximum of uncertainty of 10%, the trial should include a minimum of 100 patients. Assuming a dropout rate of 20%, a total of 125 subjects should be enrolled into the study.

All analyses were based on the intention-to-treat (ITT) analysis set, which was defined as patients that have received at least one PAHG injection.

The subjective responder rate at 6 and 12 months was estimated using a logistic regression with time as fixed effect. Change from baseline in the ICIQ scores was analyzed by the Wilcoxon signed-rank test. Each of the three ICIQ questions, as well as their total sum score, was analyzed separately. Urine leakage (pad test) was analyzed in an ANOVA model with time as fixed effect. Number of incontinence episodes was evaluated in a generalized linear model for repeated measurements assuming a Poisson distribution and a covariance matrix with compound symmetry structure. Estimated changes from baseline are presented as ratios (estimate post-baseline compared to baseline). Three VAS scores measuring QoL as a result of overall incontinence, stress incontinence, or urge incontinence were analyzed separately in an ANOVA model with time and baseline VAS score as fixed effects. PVR, the proportion of subjects receiving a second injection of PAHG, duration of the injection procedure, and the surgeons' satisfaction with the injection technique were summarized using descriptive statistics.

Missing values were imputed with the last observation carried forward (LOCF) in the analyses of the responder rate and ICIQ. For repeated measurements, missing values were not imputed with the LOCF. Instead, they were dealt with inside the model. Repeated measurement analyses were performed for urine leakage (pad test), incontinence episodes, and QoL parameters.

**Additional analyses** Additional analyses were performed to evaluate the effect of other variables in the treatment outcome. Responder rate was assessed on data sets stratified by: type of urine incontinence (stress versus mixed), number of treatments (one vs two), and number of PAGH injection procedures performed per center (\<15 injections (low volume) versus ≥15 injections (high volume)). Analyses were based on a logistic regression model with missing responder values imputed with LOCF. As supportive analysis of the primary analysis, the logistic regression model was expanded by incorporating the covariates age and BMI as continuous variables, in separate analyses.

**Ethical assurances** The study was conducted in accordance with the Declaration of Helsinki II 1964, as amended in Scotland, October 2000, the Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (commonly known as the Medical Device Directive), and the international ISO standard ISO/DIS 14155-1 + 2:2003 clinical investigation of medical devices for human subjects. The clinical investigation plan was submitted to all local ethics committees. Written informed consent was obtained from all patients after written and verbal information about the study, procedures, potential risks, or inconveniences, and expected benefits.

Results {#Sec6}
=======

One hundred thirty-five women (67 with stress and 68 with mixed incontinence) were recruited and treated with PAHG. Table [1](#Tab1){ref-type="table"} outlines the patients' demographic and baseline measurements. Table 1Demographic and incontinence-related characteristics of the ITT population at baselineDemographic and baseline measurements (*N* = 135)MedianRangeAge (years)5629--82Weight (kg)7654--106BMI (kg/m^2^)2720--40Length of incontinence (years)61--39Maximal urine flow (ml/s)2815--87Daily diuresis per kg (ml/kg/24 h)239--78Bladder capacity (ml)500250--1,200PVR (ml)200--100

Ninety-eight patients completed the study, 36 withdrew, and one patient failed to attend only the 12 months follow-up visit. One patient withdrew due to an AE (aggravated urine incontinence), 11 due to insufficient effect, and six due to protocol violations. Three patients were lost to follow-up, three withdrew their informed consent, and 12 withdrew for other reasons.

The ITT analysis set included 135 patients, and the per protocol analysis set included 94 patients (four of the 98 patients who completed the study had protocol violations, but were allowed to continue in the safety analyses of the study).

The median of total injected volume of PAHG per treatment was 1.5 ml (range 0.8--3 ml). The median volume per deposit was 0.5 ml.

Efficacy {#Sec7}
--------

Responder rates (cured/improved) after 1 month, 6 months, and 12 months were 87%, 71%, and 66%, respectively. The corresponding fractions of totally cured patients were 27%, 16%, and 24%, respectively. At 12 months, 19 patients were categorized as non-responders, 17 showed "no-change", and two worsening of symptoms. The subjective responder rate at 12 months was 70% among patients with stress incontinence compared to 63% among those with mixed incontinence. The responder rate at 12 months was higher among those receiving one treatment than among receiving two (71% vs 57%, *p* = 0.0058). The responder rate after 12 months was 58% among women treated at a low volume center (\<15 injections), and 69% among those treated at a high volume center (≥15 injections). This difference is of borderline statistical significance (*p* = 0.0974).

No significant relationships could be found between the responder rate and age, BMI, or injected PAGH volume.

The median ICIQ score (three questions shown in Table [2](#Tab2){ref-type="table"}) decreased by approximately 50% at 1, 6, and 12 months follow-up (*p* \< 0.0001). The overall QoL VAS score decreased significantly from a baseline median of 72 to 19, 22, and 20 after 1 month, 6 months, and 12 months follow-up, respectively. The corresponding stress component score was improved from a baseline median of 81 to 18, 22, and 18, and the urge component score from a baseline median of 40 to 9, 7, and 6 after 1, 6, and 12 months, respectively. Table 2Medians of the ICIQ scores at baseline, 1, 6, and 12 months follow-up in the ITT analysis setQuestionBaseline1 month6 months12 monthsHow often do you leak urine? (range 0--5)4.01.02.02.0How much urine do you usually leak? (range 0--6)4.02.02.02.0How much does leaking urine interfere with your everyday life? (range 0--10)8.02.03.03.0Total (range 0--21)15.06.0707.0All scores were significantly decreased at all follow-up visits (*p* \< 0.0001)

The median number of incontinence episodes/24 h decreased in the group as a whole from 3.0 (range 0.0--14.7) at baseline to 0.7 (range 0.0--16.0) at 1 month, 6 months, and 12 months (*p* \< 0.0001 vs baseline). In 72% of the patients, number of incontinence episodes decreased by at least 50%. The median number of stress episodes decreased from 1.3 (range 0--8) at baseline to 0.0 (range 0.0--13.0) at 12 months, while the median number of urge incontinence episodes decreased from 0.7 (range 0.0--8.7) at baseline to 0.0 (range 0.0--7.7) at 12 months.

The median urine leakage/24 h was significantly reduced after treatment in the group as a whole, ranging from 29 g (range 1--552) at baseline to 4g (range 0--347) at 1 month, 5g (range 0--150) at 6 months, and 4 g (range 0--144) at 12 months (*p* \< 0.0001 vs baseline). Thus, the urine leakage/24 h was reduced by approximately 85%, and 69% of the patients had at least 50% decrease in urine leakage.

The median PVR was unchanged during the study (baseline 20 ml (range 0--100), 1 month, 8 ml (range 0--158), 6 months, 12 ml (range 0--116), and 12 months, 11 ml (range 0--131)).

The total number of injections was 182, as 47 out of the 135 patients (35%) received PAHG reinjections.

The injection procedure took a median time of 7 min (range 2--20 min).

Surgeon satisfaction with the injection procedure was 82 (range 34--100), as measured by VAS of 100 mm.

Safety {#Sec8}
------

Of the 135 patients, 59 experienced an AE. The total number of events were 96, of which 88 were non-serious AEs (57 patients), and eight were serious (eight patients). Out of 88 non-serious AEs, 32 were classified as possibly (19), or probably (11) related to the treatment (Table [3](#Tab3){ref-type="table"}). Table 3Summary of the 32 reported treatment-related adverse events which occurred after 182 injectionsAdverse eventsNo. of occurrencesUTI10Injection site pain5Urinary retention2^a^Voiding difficulties2^b^Past void residual \>100 ml2^c^Haematuria2Urine incontinence aggravated2De novo urge incontinence2Injection site laceration1Headache4^a^Classified as serious due to hospitalization, recovered within 6 and 9 days, respectively^b^Not catheterized^c^Catheterized 2 and 4 times within 3 days, respectively

Out of the 32 treatment-related AEs were 10 cases of UTI, nine with postprocedural pain, two of urinary retention, two of transurethral catheterization, two of hematuria, two of aggravated incontinence, two of de novo urge incontinence, and one of injection-site rupture. Two out of eight serious AEs were treatment-related. Both of them were urinary retention, which had resolved within 6 and 9 days, respectively.

Discussion {#Sec9}
==========

This study has shown that the subjective and objective outcome at 12 months was similar to that shown in a previous study of 25 women with stress or mixed urine incontinence who had been injected with PAGH \[[@CR12]\], taking into account that the present results are based on ITT analysis. Not surprisingly, the outcome was consistent in those with pure stress incontinence compared to those with mixed incontinence. Our results are also comparable to reports in the literature on bulking agents \[[@CR23], [@CR24]\] and recently published article on Bulkamid \[[@CR25]\].

However, this study also showed that patients, who were treated at centers conducting fewer bulking procedures, appeared to have a poorer outcome than those treated at centers conducting higher amount of bulking procedures. This indicates that there is a learning curve for mastering injection therapy via an endoscope. Median injection time was 7 min, emphasizing the ease of the procedure, albeit performed under direct urethroscopic guidance.

Approximately 1/3 (35%) of the patients received a second injection within the first 8 weeks comparable to other studies \[[@CR23], [@CR24]\]. Remarkably, we found a significantly lower cure rate among those patients who received two treatments, indicating poor effect after the first injection as a risk factor.

We made no attempts to differentiate between pathophysiologic factors such as hypermobility and/or intrinsic sphincter deficiency, as clinical efficiency following bulking does not seem to differ among these subgroups \[[@CR26]\]. Our study comprised daily routine patients who had only been treated with noninvasive urodynamic procedures.

However, the right patient population for urethral injection treatment is still being disputed. Clinical data show that patients have a general preference for less invasive forms of therapy, and they are willing to trade a lower success rate in favor of less invasive procedures \[[@CR27]\]. However, pretreatment counseling of the patient is important for the clarification of the patient's expectations in terms of efficacy and safety.

Polyacrylamide is a polymer made of repeated units of acrylamide monomers, which are bound covalently by strong single bonds. This means that the original hazardous nature of the acrylamide monomer is no longer present. The linear chain structure of the polymer has further been folded into a three-dimensional entanglement in principal forming one huge single and very stable molecule. The total amount of residual acrylamide monomer in the PAGH Bulkamid is less than 1 mcg/1-ml product. This amount is lower than normal daily intake of acrylamide with food and drinking water. By PAGH injection, the human body is exposed to a single dose of hardly measurable amount of acrylamide, and as the molecule is resistant to degradation \[[@CR28]\], no subsequent acrylamide monomer is to be expected.

Acrylamide is classified as a potential carcinogenic substance since it was shown to induce cancer in rodents. However, since no conclusive connection was proven even between intake of high doses of acrylamide and cancer \[[@CR29], [@CR30]\], there is no scientific evidence to suspect PAGH being carcinogenic.

PAHG seems to have many of the ideal properties of a bulking agent \[[@CR31]\]. It does not contain microparticles, which are shown to provoke a foreign body reaction and give rise to fibrosis and calcifications, and is highly biocompatible, not evoking hypersensitivity or granuloma formation. It also exerts a favorable anatomical integrity by allowing invasion of macrophages and giant cells that are gradually replaced by a thin, vessel-bearing fibrous network \[[@CR15], [@CR16]\].

The volume of some of the other more common bulking agents may reduce significantly with time \[[@CR32]\]. PAGH, in the opposite, remains stable in volume for years \[[@CR15]\], most likely due to a constant exchange of its water molecules with those of surrounding tissue extracellular matrix. \[[@CR33]\].

In this study, the material was injected in the upper third of the urethra, but a recent study seems to indicate that the bulking effect can be improved by injecting into the mid urethral zone \[[@CR34]\].

The median amount of PAHG injected per treatment was 1.5 ml, which is similar to what has been reported previously \[[@CR12]\]. This is however significantly less than commonly reported from other materials \[[@CR24]\]. Too much material injected per site may increase the risk of material leakage, either via the injection hole, or due to rupture, or necrosis of the covering mucosa. No clear standard exists for the optimal relationship between amount of injected material and cure rate \[[@CR24]\].

PAHG can be visualized ultrasonographically enabling monitoring during the injection procedure. This is a significant advantage especially in case of reinjection, but also in case of material retraction, if too much material has been injected (author's personal experience).

PAHG therapy did not change PVR, indicating no influence on bladder emptying. This is in accordance with previously reported pressure-flow data \[[@CR12]\].

All AEs were generic and not related to the material. The most common AE (10/182 injections) was UTI, despite the use of prophylactic antibiotics. Eight patients experienced problems with bladder emptying---all transient and possibly due to the injection of the local anesthetic along the urethra and hence, interference with its afferent activity. Removal of injected material was not necessary in any case, and specific injection site or product-specific AEs were not found, suggesting a high safety profile of the material.

This study confirms that approximately two out of three women with uncomplicated stress or mixed incontinence can be improved or cured by PAHG injection therapy, and that the results sustain for at least 1 year postoperatively. The procedure is quick and easy to perform and therefore, well accepted by the physician. The PAGH safety profile seems unique, as no injection site or product-specific AEs were seen.
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